NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Entera Bio Ltd. (ENTX) Stock Analysis

Entera Bio Ltd. (ENTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ENTX

$3.00

+$0.05 (+1.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENTX with… →

ENTX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.95
Previous Close
$2.95
Day's Range
2.88–3.15
52-Week Range
0.91–4.20
Volume
603.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.39
Valuation
Market Cap
$519.43M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.36
Financials (FY)
Revenue (FY)
$42.00K−76.80%
Net Income (FY)
−$11.44M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
173.14M
1-Year Return
+38.89%
Dividend and dates
Avg Volume
2.63M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ENTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+54.64%
2025−8.49%
2024+253.33%
2023−17.81%
2022−74.07%
2021+160.65%
2020−49.53%
2019−29.84%
2018 (partial year)−51.43%

As of September 4, 2026.

ENTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$42.00K−$11.44M−27235.7%
2024$181.00K−$9.54M−5271.3%
2023$0.00−$8.89M—
2022$134.00K−$13.07M−9754.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$42.00K$0.00−$11.53M−$11.44M−27235.7%
2024$181.00K$9.00K−$9.59M−$9.54M−5271.3%
2023$0.00$0.00−$8.89M−$8.89M—
2022$134.00K$33.00K−$13.02M−$13.07M−9754.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ENTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricENTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Entera Bio Ltd. (ENTX) at $519.43M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 20.

The 52-week range on file runs from $0.91 to $4.20. The most recent close on file for ENTX is $3.00, dated September 4, 2026. That is +$0.05 (+1.69%) against the previous close. The latest close sits 229.67% above that 52-week low.

Financial Health

In fiscal 2025, Entera Bio Ltd. reported revenue of $42.00K. That is −76.80% against the prior fiscal year, when revenue was $181.00K. The same year closed with a net loss of $11.44M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.36.

Across the 4 fiscal years on file, revenue moves from $134.00K in 2022 to $42.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +38.89%. Across 5 years the annualized return works out at −10.03%. Beta against the wider market is reported at 1.39. Daily returns over the trailing 8 years annualize to a volatility of 114.48%.

Growth & Income

The record shows no dividend for ENTX.

Across the complete calendar years on file, 2024 returned +253.33% and 2022 returned −74.07%. Of the 7 complete calendar years on file, 2 finished higher. So far in 2026 the price is +54.64%.

Peer Comparison

Entera Bio Ltd. (ENTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Entera Bio Ltd. ENTX $519.43M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Entera Bio Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Entera Bio Ltd.

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Visit website →